Copy Number Amplification of ENSA Promotes the Progression of Triple-negative Breast Cancer Via Cholesterol Biosynthesis

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Feb 11

PMID 35145111

Authors

Yi-Yu Chen

Jing-Yu Ge

Si-Yuan Zhu

Zhi-Ming Shao

Ke-Da Yu

Affiliations

Soon will be listed here.

Abstract

Copy number alterations (CNAs) are pivotal genetic events in triple-negative breast cancer (TNBC). Here, our integrated copy number and transcriptome analysis of 302 TNBC patients reveals that gene alpha-endosulfine (ENSA) exhibits recurrent amplification at the 1q21.3 region and is highly expressed in TNBC. ENSA promotes tumor growth and indicates poor patient survival in TNBC. Mechanistically, we identify ENSA as an essential regulator of cholesterol biosynthesis in TNBC that upregulates the expression of sterol regulatory element-binding transcription factor 2 (SREBP2), a pivotal transcription factor in cholesterol biosynthesis. We confirm that ENSA can increase the level of p-STAT3 (Tyr705) and activated STAT3 binds to the promoter of SREBP2 to promote its transcription. Furthermore, we reveal the efficacy of STAT3 inhibitor Stattic in TNBC with high ENSA expression. In conclusion, the amplification of ENSA at the 1q21.3 region promotes TNBC progression and indicates sensitivity to STAT3 inhibitors.

Citing Articles

Raddeanin A promotes the apoptosis of gastric cancer in conjunction with autophagy inhibitor Hydroxychloroquine via MAPK signaling pathway.

Teng Y, Xing Y, Xue W, Hu Y, Li Z, Qian J J Tradit Complement Med. 2025; 15(2):161-169.

PMID: 40060151 PMC: 11883627. DOI: 10.1016/j.jtcme.2024.07.004.

Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma.

Takagi S, Nakajima M, Koike S, Takami M, Sugiura Y, Sakata S Oncogene. 2024; .

PMID: 39663392 DOI: 10.1038/s41388-024-03251-6.

Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple-Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1-Regulated Cholesterol Metabolism.

Yang Y, Liao J, Pan Z, Meng J, Zhang L, Shi W Adv Sci (Weinh). 2024; 12(5):e2413103.

PMID: 39656925 PMC: 11791979. DOI: 10.1002/advs.202413103.

Tumor-derived miR-9-5p-loaded EVs regulate cholesterol homeostasis to promote breast cancer liver metastasis in mice.

Li M, Hu S, Lei H, Yuan M, Li X, Hou W Nat Commun. 2024; 15(1):10539.

PMID: 39627188 PMC: 11615374. DOI: 10.1038/s41467-024-54706-z.

Ketogenesis promotes triple-negative breast cancer metastasis via calpastatin β-hydroxybutyrylation.

Jiang H, Zeng Y, Yuan X, Chen L, Xu X, Jiang X Lipids Health Dis. 2024; 23(1):371.

PMID: 39533307 PMC: 11555945. DOI: 10.1186/s12944-024-02364-x.

References

Venkitaraman R . Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Expert Rev Anticancer Ther. 2010; 10(2):199-207. DOI: 10.1586/era.09.189. View

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

Yin W, Lu J, Di G, Lin Y, Zhou L, Liu G . Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat. 2008; 115(2):325-33. DOI: 10.1007/s10549-008-0096-0. View

Bianchini G, Balko J, Mayer I, Sanders M, Gianni L . Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13(11):674-690. PMC: 5461122. DOI: 10.1038/nrclinonc.2016.66. View

Carey L, Winer E, Viale G, Cameron D, Gianni L . Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol. 2010; 7(12):683-92. DOI: 10.1038/nrclinonc.2010.154. View

Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X . Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019; 35(3):428-440.e5. DOI: 10.1016/j.ccell.2019.02.001. View

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

Lehmann B, Jovanovic B, Chen X, Estrada M, Johnson K, Shyr Y . Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6):e0157368. PMC: 4911051. DOI: 10.1371/journal.pone.0157368. View

10.

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J . The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PMC: 2826709. DOI: 10.1038/nature08822. View

11.

Stratton M, Campbell P, Futreal P . The cancer genome. Nature. 2009; 458(7239):719-24. PMC: 2821689. DOI: 10.1038/nature07943. View

12.

Hieronymus H, Schultz N, Gopalan A, Carver B, Chang M, Xiao Y . Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A. 2014; 111(30):11139-44. PMC: 4121784. DOI: 10.1073/pnas.1411446111. View

13.

Bergamaschi A, Kim Y, Wang P, Sorlie T, Hernandez-Boussard T, Lonning P . Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 2006; 45(11):1033-40. DOI: 10.1002/gcc.20366. View

14.

Ciriello G, Miller M, Aksoy B, Senbabaoglu Y, Schultz N, Sander C . Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45(10):1127-33. PMC: 4320046. DOI: 10.1038/ng.2762. View

15.

Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne C, Rimawi M . Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2019; 17(4):233-250. PMC: 8023395. DOI: 10.1038/s41571-019-0299-9. View

16.

Chin K, DeVries S, Fridlyand J, Spellman P, Roydasgupta R, Kuo W . Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10(6):529-41. DOI: 10.1016/j.ccr.2006.10.009. View

17.

Kuzu O, Noory M, Robertson G . The Role of Cholesterol in Cancer. Cancer Res. 2016; 76(8):2063-70. PMC: 5813477. DOI: 10.1158/0008-5472.CAN-15-2613. View

18.

Nelson E, Wardell S, Jasper J, Park S, Suchindran S, Howe M . 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013; 342(6162):1094-8. PMC: 3899689. DOI: 10.1126/science.1241908. View

19.

Borgquist S, Giobbie-Hurder A, Ahern T, Garber J, Colleoni M, Lang I . Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. J Clin Oncol. 2017; 35(11):1179-1188. DOI: 10.1200/JCO.2016.70.3116. View

20.

Baek A, Yu Y, He S, Wardell S, Chang C, Kwon S . The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017; 8(1):864. PMC: 5636879. DOI: 10.1038/s41467-017-00910-z. View